Bristol-Myers Squibb vs ICICI Bank: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bristol-Myers Squibb and ICICI Bank side by side

1. 1858Bristol-Myers Squibb

   Edward Robinson Squibb opens his Brooklyn laboratory

   Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.

2. 1887Bristol-Myers Squibb

   Bristol and Myers buy the Clinton Pharmaceutical Company

   Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.

3. 1898Bristol-Myers Squibb

   Bristol, Myers and Company is named

   The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.

4. 1944Bristol-Myers Squibb

   Penicillin at wartime scale

   Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.

5. 1955ICICI Bank

   ICICI Founded as Development-Finance Institution

   ICICI was formed to provide medium- and long-term project finance to Indian businesses.

6. 1989Bristol-Myers Squibb

   Bristol-Myers and Squibb merge

   Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.

7. 1994ICICI Bank

   ICICI Bank Incorporated

   ICICI Bank was incorporated as part of the ICICI group during India's post-liberalization banking opening. The move gave ICICI a deposit-taking commercial bank able to serve retail, corporate, and transaction-banking customers.

8. 1999ICICI Bank

   NYSE Listing Milestone

   ICICI became the first Indian company and the first bank or financial institution from non-Japan Asia to list on the New York Stock Exchange. The listing expanded global visibility and imposed a higher disclosure profile on the group.

9. 2001ICICI Bank

   Bank of Madura Amalgamation

   Bank of Madura was amalgamated with ICICI Bank with effect from March 10, 2001. The deal added branches, customers, and a southern India presence that helped the young bank build distribution faster than organic expansion alone.

10. 2002ICICI Bank

    Reverse Merger Created Universal Bank

    ICICI, ICICI Personal Financial Services, and ICICI Capital Services merged into ICICI Bank.

11. 2006Bristol-Myers Squibb

    CEO Peter Dolan removed over the Plavix deal

    After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.

12. 2009Bristol-Myers Squibb

    Medarex bought and Mead Johnson split off

    BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.

13. 2010ICICI Bank

    Bank of Rajasthan Merger

    The Bank of Rajasthan merger strengthened ICICI Bank's branch network, especially in northern and western India. The transaction mattered because local branches and deposits still supported private-bank scale even as digital channels were growing.

14. 2011Bristol-Myers Squibb

    FDA approves Yervoy

    Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.

15. 2012Bristol-Myers Squibb

    FDA approves Eliquis

    The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.

16. 2014Bristol-Myers Squibb

    FDA approves Opdivo

    The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.

17. 2018ICICI Bank

    Sandeep Bakhshi Became MD and CEO

    Sandeep Bakhshi became Managing Director and CEO in October 2018 after Chanda Kochhar requested early retirement. His tenure has been associated with a sharper focus on risk controls, asset quality, governance, and steady retail-led growth.

18. 2019Bristol-Myers Squibb

    Celgene acquisition closes

    BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.

19. 2020Bristol-Myers Squibb

    MyoKardia deal and a GAAP loss

    BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.

20. 2022Bristol-Myers Squibb

    Turning Point bought as Revlimid generics arrive

    BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.

21. 2023Bristol-Myers Squibb

    Chris Boerner becomes CEO

    Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.

22. 2024Bristol-Myers Squibb

    Karuna, Mirati and RayzeBio close; Cobenfy approved

    The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.

23. 2025Bristol-Myers Squibb

    BioNTech partnership, Orbital deal and $48.2B revenue

    BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.

24. 2025ICICI Bank

    FY2025 Balance Sheet Scale

    The FY2025 integrated report listed Rs 16,103.48B in deposits, Rs 13,417.66B in loans and advances, Rs 21,182.40B in standalone total assets, and a 16.55% capital adequacy ratio.

25. 2025ICICI Bank

    FY2025 Profitability

    ICICI Bank reported Rs 472.27B in standalone profit after tax and Rs 510.29B in consolidated profit after tax for FY2025. Profitability matters because the bank has to fund technology, compliance, provisions, and growth while keeping capital strong.

26. 2025ICICI Bank

    IMobile and Card Scale

    IMobile processed 558M transactions worth Rs 11,238B in FY2025, and the bank had close to 18M active credit cards at March 31, 2025.

27. 2026Bristol-Myers Squibb

    Guidance raised and merger reports denied

    On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.

28. 2026ICICI Bank

    Q1 FY2027 Profit Up 15.9%

    Standalone profit rose 15.9% to Rs 14,805 crore for April-June 2026, with net interest income up 12.7% and net NPAs at 0.35%.

29. 2026ICICI Bank

    Bakhshi Reappointed to 2028

    The RBI approved Sandeep Bakhshi's reappointment as MD and CEO for two years from October 4, 2026.

30. 2026ICICI Bank

    FY2026 Profit Crosses Rs 50,000 Crore

    Standalone net profit rose 6.2% to Rs 50,146.6 crore in FY2026, with a 4.32% net interest margin and 15.8% loan growth.

Acquisitions

Questions about Bristol-Myers Squibb vs ICICI Bank